This article was originally posted on May 3.

Fluidigm continues to benefit from its efforts to serve single-cell genomics researchers.

The South San Francisco, Calif.-based biochip company last week reported a 33-percent spike in first quarter revenues, driven by sales of its C1 Single-Cell AutoPrep System, as well as increased demand for its integrated fluidic circuit chips from its agricultural and clinical laboratory clients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.